Related Experiment Video

Updated: Jul 8, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with

Lorenzo M Leoni1, Brandi Bailey, Jack Reifert

  • 1Salmedix, acquired by Cephalon, Inc., Frazer, Pennsylvania, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|January 4, 2008
PubMed
Abstract

Insights

Bendamustine exhibits unique anticancer mechanisms, distinct from other DNA-alkylating agents. It activates DNA damage response and apoptosis, inhibiting cell division and promoting cell death.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Chemotherapy

Background:

  • Bendamustine demonstrates clinical efficacy in patients with chemotherapy-refractory diseases.
  • Understanding the precise mechanisms of action is crucial for optimizing its therapeutic use.

Purpose of the Study:

  • To elucidate the mechanisms of action of bendamustine.
  • To compare bendamustine's activity with structurally related DNA-alkylating agents.

Main Methods:

  • Bendamustine was evaluated using the National Cancer Institute's in vitro antitumor screen.
  • Techniques included gene expression profiling, real-time PCR, immunoblotting, cell cycle analysis, and DNA damage repair assays.
  • Comparisons were made with chlorambucil and phosphoramide mustard.

Main Results:

  • Bendamustine exhibits a unique activity profile, distinct from other DNA-alkylating agents.
  • Mechanisms involve activating DNA-damage stress response, apoptosis, inhibiting mitotic checkpoints, and inducing mitotic catastrophe.
  • Bendamustine activates base excision DNA repair, unlike the alkyltransferase repair mechanism of other alkylators.

Conclusions:

  • Bendamustine possesses distinct mechanistic features compared to other alkylating agents.
  • These unique properties may contribute to its observed clinical efficacy.

Related Concept Videos

Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Other Unique Bacteria01:18

Other Unique Bacteria

Magnetic bacteria exhibit a directed movement called magnetotaxis, driven by structures called magnetosomes. These magnetosomes consist of chains of magnetic particles made of either magnetite (Fe₃O₄) or greigite (Fe₃S₄) and are organized in a linear conformation by a protein scaffold within invaginations of the cell membrane. The bacteria align along the north–south magnetic field lines, much like a compass needle. They are typically microaerophilic or anaerobic and are commonly found near the...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...